Antisense Therapeutics is a biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such as Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, Cis-UCA emulsion cream for atopic dermatitis, and CDNF for amyotrophic lateral sclerosis (ALS). The company was founded by Eero Hemminki Castren, Henri Juhani Huttunen, Heikki Rauvala, and Mart Saarma in 2008 and is headquartered in Espoo, Finland.

Since its founding in 1955, REYON Pharmaceutical has continued to innovate and take new leaps forward. Based on our research, production, and sales capabilities from API to Drug product using purely our own technology, we are leaping to become the global No. 1 bio & chemical pharmaceutical company in various areas including next-generation biopharmaceuticals, from gene therapy, to antibody therapy, cell therapy, and natural medicine.

ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.

Pharmasonics develops, manufactures and plans to market power ultrasonic interventional cardiology devices to address the problem of restenosis in coronary arteries. Their lead product aims to reduce the rate of restenosis after intervention by applying a therapeutic level of ultrasound radiation to the target lesion

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Oncogene Science, Inc. provided cancer diagnostics services. The company was founded in 1983 and was headquartered in Uniondale, NY.

HuBit Genomix KK is a Japanese company located in Tokyo specializing in commercial physical and biological research. Celera Group acquired HuBit Genomix KK on March 20, 2001.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing.\nThe company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki.\nHermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals.\nHermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

LG H&H Co., Ltd. engages in the production and sale of household goods and cosmetic products. It operates through following divisions Beauty, Health and Refreshment businesses. The Beauty business division provides anti-aging cosmetic products. The Health division markets healthcare, skincare and household products. The Refreshment division provides soda, juice, energy drinks and other beverages. The company was founded on April 3, 2001 and is headquartered in Seoul, South Korea.

The Feinstein Institutes for Medical Research comprise the research arm of Northwell Health. Feinstein is home to 50 research labs, 2,500 clinical research studies, and 4,000 professional and support staff. Feinstein researchers have made breakthroughs in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine, among others, and continue work in those and other areas. Feinstein is the laboratory and faculty home of the Elmezzi Graduate School of Molecular Medicine. Additionally, students without an MD degree may earn a PhD in molecular medicine via the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, as part of the medical school's MD/PhD or PhD programs.

Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. Qilu focuses on the development, manufacturing and marketing of generic drugs and active pharmaceutical ingredients(APIs) in therapeutic areas including but not limited to Oncology, Cerebrovascular & Cardiovascular, Anti-infections, Psychological & Neurological Systems, Respiratory System, and Ophthalmological Diseases. Qilu has more than 15,000 employees, 70% of whom have a college degree or above. Qilu Pharmaceutical consistently focuses on revolutionary development strategies guided by market demand and product innovation. Qilu has established extensive cooperation with domestic and international partners on multiple R&D projects. Devoted to the cultivation of talent, Qilu has invested in a highly qualified R&D team and efficient R&D capabilities. The 200+ new drug products successfully developed by Qilu constitutes as a large part of future production and sales for Qilu Pharmaceutical and partners. A number of technological achievements have garnered national and provincial scientific and technological progress awards for Qilu.

Oxford Biomedica (UK) Ltd., part of Oxford Biomedica Plc, is a company headquartered in Oxford, UK. The firm develops novel gene therapy products and treatment for cystic fibrosis.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Aiji Taikang (Jiaxing) Biotechnology Co., Ltd., established on 2019-05-13, Business scope includes biological reagents,Production and sales of Class I medical devices(The above does not contain hazardous chemicals and precursor chemicals);biotechnology development,Technology Promotion,technical consulting,Technical Services;software development,Basic software service,Application software service,Computer System Services,data processing services;Sales:Instrumentation,Computer hardware and software and auxiliary equipment,Stationery;Undertake exhibition and display activities;Conference Services;Import and export business of self-operated and agent goods and technologies.(Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Institutes for Biological Sciences CAS is a private company headquartered in Shanghai, China, that operates as researching agency.

Suzhou Hopu Huikang Biomedical Technology Co., Ltd., established on 2021-07-22, Business scope includes licensed projects:Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Research and development of bio-based materials technology;Sales of bio-based materials;Cosmetics Wholesale(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)